long-term survival

Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension

McLaughlin VV, Howard L, Elwing J, Fernandes CC, Gaine S, Galiè N, Oudiz RJ, Stefani M, Stickel S, Strachan P, Tamura Y, Kim NH. Evaluating[...]

By afschroeder • November 17, 2025

Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial

Rosenberg JE, Galsky MD, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, van der Heijden MS, Dreicer R, Durán[...]

By sjmartinez • December 8, 2024